Michael J. Absalon, MD, PhD
focuses on developing new therapies and combinations of therapies for pediatric leukemias and lymphomas. He is currently investigating the therapeutic potential of combining the new targeted drug sorafenib with conventional chemotherapy for relapsed AML.
513-636-4266
michael.absalon@cchmc.org
Michael J. Absalon, MD, PhD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Relapsed leukemia; lymphoma; new therapeutics; ataxia telangiectasia; DNA damage response mechanisms
Education and Training
BS: Lewis and Clark College, Portland, OR, 1987. PhD: Massachusetts Institute of Technology, Cambridge, MA, 1994. MD: Oregon Health Sciences University, Portland, OR, 1998. Fellowship: St. Jude Children's Research Hospital, Memphis, TN, 2005.
Publications
View PubMed Publications
Absalon MJ, Smith FO. Treatment strategies for pediatric acute myeloid leukemia. Expert Opin Pharmacother. 2009 Jan;10(1):57-79.
Absalon MJ, McCarville MB, Liu T, Santana VM, Daw NC, Navid F. Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma. Pediatr Blood Cancer. 2008 Jun;50(6):1147-53. Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell. 2005 Oct 7;123(1):49-63. Absalon MJ, Harding CO, Fain DR, Li L, Mack KJ. Leigh syndrome in an infant due to mitochondrial DNA depletion. Pediatr Neurology. 2001; 24:60-63.
|
Denise M. Adams, MD
Marjory J. Johnson Chair of Vascular Tumor Translational Research
is a nationally recognized expert on vascular anomalies with a keen interest in rare vascular tumors and life threatening malformations. She leads a clinical and translational research program to develop new therapies for these conditions and currently is the PI of a clinical study of sirolimus, a mTOR inhibitor, in the treatment of complicated vascular anomalies, the first trial of a new therapy for these conditions.
513-636-4266
denise.adams@cchmc.org
Denise M. Adams, MD
Marjory J. Johnson Chair of Vascular Tumor Translational Research
Medical Director, Comprehensive Hemangioma and Vascular Malformation Center
Fellowship Director, Hematology / Oncology
Academic Information
Professor, UC Department of Pediatrics
Show All
Biography
Denise Adams, MD, is fellowship director of the Hematology / Oncology Fellowship Program and medical director of the Hemangioma and Vascular Malformations Center at Cincinnati Children’s. One of the vascular team’s main priorities has been establishing standards of care for patients with these diagnoses so they can follow outcome measures. Of key interest to Dr. Adams, as an oncologist, is the improvement in care of patients with kaposiform hemangioendotheliomas (KHE). The team of experts has established a clinical registry for these patients to gain insight into the clinical characteristics of KHE patients and the long term outcomes of these patients. They also have a phase II FDA funded trial for complicated vascular anomalies and KHE patients are included in this trial. These tumors are rare but have a very high mortality and morbidity rate. It is important that the group learn more about the clinical characteristics, phenotype, biomarkers which can lead to further investigations and clinical trials.
Education and Training
MD: Georgetown University School of Medicine, 1988.
Post-Graduate: Georgetown University, 1983.
BSN: Georgetown University, 1982.
Publications
View PubMed Publications
Quarmyne MO, Gupta A, Adams DM. Lymphangiosarcoma of the thorax and thoracic vertebrae in a 16-year-old girl. J Clin Oncol. 2012 Oct;30(29):294-8. Haggstrom AN, Beaumont JL, Lai JS, Adams, DM, Drolet BA, Frieden IJ, Garzon MC, Holland KE, Horii KA, Lucky AW, Mancini AJ, Metry DW, Morel KD, Newell BD, Nopper AJ, Siegel D, Swigonski NL, Cella D, Chamlin SL. Measuring the severity of infantile hemangiomas: instrument development and reliability. Arch Dermatol. 2012 Feb;148(2):197-202. Fadell MF 2nd, Jones BV, Adams DM. Prenatal diagnosis and postnatal follow-up of rapidly involuting congenital hemangioma (RICH). Pediatr Radiol. 2011 Aug;41(8):1057-60. Maugans T, Sheridan RM, Adams D, Gupta A. Cutaneous vascular anomalies associated with neural tube defects: nomenclature and pathology revisited. Neurosurgery. 2011 Jul;69(1):112-8. Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, Dasgupta R, Azizkhan RG, Adams DM. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011 Mar 28. Epub ahead of print. Adams DM. Special considerations in vascular anomalies: hematologic management. Clin Plast Surg. 2011 Jan;38(1):153-60. Duffy KJ, Runge-Samuelson C, Bayer ML, Friedland D, Sulman C, Chun R, Kerschner JE, Metry D, Adams D, Drolet BA. Association of hearing loss with PHACE syndrome. Arch Dermatol. 2010 Dec;146(12):1391-6.
Drolet BA, Chamlin SL, Garzon MC, Adams D, Baselga E, Haggstrom AN, Holland KE, Horii KA, Juern A, Lucky AW, Mancini AJ, McCuaig C, Metry DW, Morel KD, Newell BD, Nopper AJ, Powell J, Frieden IJ. Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin. J Pediatr. 2010 Nov;157(5):789-94. Lomenick JP, Reifschneider KL, Lucky AW, Adams D, Azizkhan RG, Woo JG, Backeljauw PF. Prevalence of adrenal insufficiency following systemic glucocorticoid therapy in infants with hemangiomas. Arch Dermatol. 2009 Mar;145(3):262-6. Dickie B, Dasgupta R, Nair R, Alonso MH, Ryckman FC, Tiao GM, Adams DM, Azizkhan RG. Spectrum of hepatic hemangiomas: management and outcome. J Pediatr Surg. 2009 Jan;44(1):125-33.
Grants
Phase II Study of Rapamycin for Complicated Vascular Anomalies. Food and Drug Administration. Sep 2009 - Aug 2013. #R01 FD 003712.
|
Karen C. Burns, MD, MS
Medical Director, Cancer Survivor Center
conducts research on cancer survivorship and serious late effects of cancer treatment, including obesity, heart problems, fertility issues, increased risk of second cancers, and long-term outcomes of cancer survivors. She is also leading development of a fertility preservation program for children and adolescents undergoing chemotherapy as well as other unique medical and support services for adolescent and young adult cancer patients.
513-636-4266
karen.burns@cchmc.org
Karen C. Burns, MD, MS
Medical Director, Cancer Survivor Center
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Education and Training
BA: University of Pennsylvania, Philadelphia, PA, 1995.
MD: Temple University, Philadelphia, PA, 1999.
Residency: Pediatrics, St. Christopher's Hospital for Children in Philadelphia, PA, 2002.
MS: Medical College of Wisconsin, 2005.
Fellowship: Medical College of Wisconsin, 2005.
Publications
View PubMed Publications
Burns K, Broudreau C, Panepinto J. Attitudes Regarding Fertility in Adolescent Females Diagnosed with Cancer. J Pediatr Hematol Oncol. 2006 Jun;28(6): 350-354. Burns K and Camitta B. Pyrite or True Gold? Journal of Pediatric Hematology/Oncology. 2005 May;27(5): 244.
|
Lionel M.L. Chow, MD, PhD
studies high grade gliomas, which are aggressive brain tumors in adults and children with limited treatment options. Using a combination of novel and robust laboratory models coupled with the study of human tumor material, the lab’s goals are to better understand the cellular origins and molecular underpinnings of these diseases in order to design and test novel therapies that will hopefully improve patient outcome. Visit the Chow Lab
513-803-1369
lionel.chow@cchmc.org
Lionel M.L. Chow, MD, PhD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsPediatric neuro-oncology Research InterestsMouse models for glioma; molecular profiling of tumor mutations; biomarkers of tumor progression; novel therapeutic agents for glioma Visit the Chow Lab
Biography
Lionel Chow, MD, PhD, received his medical and graduate degrees from McGill University in Montreal, Canada, where his research focused on the regulation of T-lymphocyte signaling by the intracellular tyrosine protein kinases Lck and Csk. Following his clinical training in Pediatrics and Pediatric Hematology / Oncology at the Hospital for Sick Children in Toronto, Canada, he moved to St. Jude Children’s Research Hospital in Memphis, Tennessee to pursue his research interests. Dr. Chow's research interests have been centered on glioblastoma multiforme, a particularly devastating form of cancer in adults and children. His work has resulted in the development of a number of novel and robust laboratory models for this disease. Using these models and interfacing with clinical trials in the Neuro-Oncology Program as well as those from national consortia such as the Children's Oncology Group (COG) and the Pediatric Brain Tumor Consortium (PBTC), Dr. Chow’s laboratory will continue research in this area with the goals of better understanding the origins of this form of cancer and improving patient outcomes.
Education and Training
PhD: McGill University, Montreal, Quebec, Canada, 1996.
MDCM: McGill University, Montreal, Quebec, Canada, 1997.
Residency: The Hospital for Sick Children, University of Toronto, Toronto, Canada, 1997-2000.
Clinical Fellowship: The Hospital for Sick Children, University of Toronto, Toronto, Canada, 2000-2003.
Postdoctoral Fellowship: St. Jude Children’s Research Hospital, Memphis, TN, 2003-2009.
Clinical Fellowship: St. Jude Children’s Research Hospital, Memphis TN, 2008-2009.
Certification: Pediatrics, 2000.
Publications
View PubMed Publications
Chow LML, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, Broniscer A, Ellison DW, Baker SJ. Cooperativity within and among Pten, p53 and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell. 2011;19:305-316.
Lavado A, Lagutin O, Chow LML, Baker SJ, Oliver G. Prox1 is required for granule cell maturation and intermediate progenitor maintenance during brain neurogenesis. PLoS Biol. 2010;8:e1000460. Cicero SA, Johnson D, Reyntjens S, Frase S, Connell S, Chow LML, Baker SJ, Sorrentino BP, Dyer MA. Cells previously identified as retinal stem cells are pigmented ciliary epithelial cells. Proc Natl Acad Sci U S A. 2009 Apr;106(16):6685-90.
Weber T, Corbett MK, Chow LML, Valentine MB, Baker SJ, Zuo J. Rapid cell-cycle reentry and cell death after acute inactivation of the retinoblastoma gene product in postnatal cochlear hair cells. Proc Natl Acad Sci U S A. 2008;105(2):781-5.
Chow LML, Zhang J, Baker SJ. Inducible Cre recombinase activity in mouse mature astrocytes and adult neural precursor cells. Transgenic Res. 2008;17(5):919-28. Chow LM, Nathan PC, Hodgson DC, Jenkin D, Weitzman S, Grant RM, Manson D, Bross A, Doyle JJ, Danjoux C, Greenberg ML. Survival and late effects in children with Hodgkin’s lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J Clin Oncol. 2006;24:5735-5741
Chow LM, Tian Y, Weber T, Corbett M, Zuo J, Baker SJ. Inducible Cre recombinase activity in mouse cerebellar granule cell precursors and inner ear hair cells. Dev Dyn. 2006;235:2991-2998. Chow LML, Baker SJ. PTEN function in normal and neoplastic growth. Cancer Lett. 2006;241:184-196.
Grants
2011 – 2014 St. Baldrick’s Foundation Scholars Award
"Molecular targeting of pediatric high-grade glioma" 2011 – 2013 Bear Necessities Pediatric Cancer Foundation
"Micro-RNA expression in pediatric high-grade glioma" 2011 – 2013 The Childhood Brain Tumor Foundation
"Micro-RNA expression in pediatric high-grade glioma" 2011 – 2015 Sontag Foundation Distinguished Scientist Award
"Molecular targeting of high-grade astrocytoma"
|
Carrye R. Cost, MD
Academic Information
Instructor, UC Department of Pediatrics
Show All
Specialties
Pediatric cancers; leukemia and lymphoma; new drug development
Biography
Carrye R. Cost, MD, earned her medical degree from Emory University School of Medicine and was a member of Alpha Omega Alpha honor medical society. She completed her residency in pediatrics and fellowship training in pediatric hematology / oncology at the University of Texas Southwestern Medical Center Dallas, where she was the recipient of multiple pediatric resident teaching awards and served as chief fellow.
Dr. Cost is currently a Hyundai Drug Development Scholar in the Cancer and Blood Diseases Institute’s Scholar Training Program in Cancer Developmental Therapeutics, engaged in translational research in leukemia, lymphoma, and other pediatric cancers, with an emphasis on new drug development and pharmacogenetics.
Education and Training
MD: Emory University School of Medicine, Atlanta, GA, 2005. Residency: Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX. Fellowship: Pediatric Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX. Certification: Pediatrics, 2008.
Publications
View PubMed Publications
Cost CR, Journeycake JM. Deep venous thrombosis screening in patients with inherited bleeding disorders and central venous catheters. Haemophilia. 2011 Mar 24. Epub ahead of print.
Cost C, Brock E, Adams-Huet B, Siegel JD, Ardura MI. 2009 pandemic influenza A (H1N1) virus infection in pediatric oncology and hematopoietic stem cell transplantation patients. Pediatr Blood Cancer. 2011 Jan;56(1):127-33.
|
Biplab Dasgupta, PhD, MS
focuses on the integration of metabolic and signaling pathways in neural cells including neural and brain cancer stem cells. He is particularly interested in understanding the link between cellular energy sensing pathways with cellular signaling circuits that are controlled by growth factors and their receptors. Mouse models are used to understand the development of high grade human and mouse brain tumor (glioma). Visit the Dasgupta Lab.
513-803-1370
biplab.dasgupta@cchmc.org
Biplab Dasgupta, PhD, MS
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Biography
Biplab Dasgupta, PhD, MS, completed his doctorate in Molecular Biology and Immunology at the Indian Institute of Chemical Biology, Calcutta, and a postdoctoral fellowship at Washington University School of Medicine, Saint Louis. Dr. Dasgupta came to Cincinnati Children's Hospital Medical Center in August 2009 as an Assistant Professor of Pediatrics. He is interested in understanding how neural cell / stem cell metabolic and energy status is linked to cell cycle, lineage commitment, differentiation and tumorigenesis. His other interests include genetic, developmental, post-translational, tissue- and stimuli–specific regulation of the subunits that constitute the AMP kinase complex.
Education and Training
PhD: Indian Institute of Chemical Biology, Calcutta, 2003
Postdoctoral Fellowship: Washington University School of Medicine, Saint Louis
Publications
View PubMed Publications
Dasgupta B, Milbrandt J. AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain development. Dev Cell. 2009 Feb;16(2):256-70. Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A. 2007 Apr;24;104(17):7217-22. Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007 Nov;6(5):363-75. Hegedus B, Dasgupta B, Shin JE, Emnett RJ, Hart-Mahon EK, Elghazi L, Bernal-Mizrachi E, Gutmann DH. Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell. 2007 Oct 11;1(4):443-57. Warrington NM, Woerner BM, Daginakatte GC, Dasgupta B, Perry A, Gutmann DH, Rubin JB. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res. 2007 Sep 15;67(18):8588-95. Dasgupta B, Gutmann DH. Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci. 2005 Jun 8;25(23):5584-94. Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005 Apr 1;65(7):2755-60. Dasgupta B, Yi Y, Hegedus B, Weber JD, Gutmann DH. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma. Cancer Res. 2005 Nov 1;65(21):9843-50.
Dasgupta B, Li W, Perry A, Gutmann DH. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res. 2005 Jan 1;65(1):236-45.
Dasgupta B, Dugan LL, Gutmann DH. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci. 2003 Oct 1;23(26):8949-54.
Dasgupta B, Roychoudhury K, Ganguly S, Akbar MA, Das P, Roy S. Infection of human mononuclear phagocytes and macrophage-like THP1 cells with Leishmania donovani results in modulation of expression of a subset of chemokines and a chemokine receptor. Scand J Immunol. 2003 Apr;57(4):366-74.
|
Rachid Drissi, PhD
studies replicative senescence or cellular aging, believed to be a tumor suppressor mechanism by which normal cells limit cell proliferation to prevent genome instability and cancer. The long-term goal of our research program is to examine telomere disruption signaling to DNA damage pathway and senescence. We are also developing a combination therapy that includes telomere disruption to improve the outcome for children with brain tumors.
513-636-4266
rachid.drissi@cchmc.org
Rachid Drissi, PhD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Education and Training
BS: University of Rouen, France, 1983.
MS: University of Rouen, France, 1984.
MS: University of Paris VI, France, 1988.
PhD: University of Paris VI, France, 1994.
Publications
View PubMed Publications
Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS. Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol. 2004 Sep 15;22(18):3790-7.
Bakkenist CJ, Drissi R, Wu J, Kastan MB, Dome JS. Disappearance of the telomere dysfunction-induced stress response in fully senescent cells. Cancer Res. 2004 Jun 1;64(11):3748-52.
Drissi R, Zindy F, Roussel MF, Cleveland JL. c-Myc-mediated regulation of telomerase activity is disabled in immortalized cells. J Biol Chem. 2001 Aug 10;276(32):29994-30001.
Stigger E, Drissi R, Lee SH. Functional analysis of human replication protein A in nucleotide excision repair. J Biol Chem. 1998 Apr 10;273(15):9337-43.
Drissi R, Lee SH. In vitro analysis of UV-damage-induced inhibition of replication. Biochem J. 1998 Feb 15;330 ( Pt 1):181-7.
Lee SH, Kim DK, Drissi R. Human xeroderma pigmentosum group A protein interacts with human replication protein A and inhibits DNA replication. J Biol Chem. 1995 Sep 15;270(37):21800-5.
Drissi R, Sor F, Nosek J, Fukuhara H. Genes of the linear mitochondrial DNA of Williopsis mrakii: coding sequences for a maturase-like protein, a ribosomal protein VAR1 homologue, cytochrome oxidase subunit 2 and methionyl tRNA. Yeast. 1994 Mar;10(3):391-8.
Grants
Telomerase: A Therapeutic Target in Pediatric Tumors. The Cure Starts Now Foundation. Sep 2010 - Oct 2011. Correlative Biology Studies in the First Phase I Trial of a Telomerase Inhibitor in Children with Recurrent Solid Tumors. CancerFree Kids Pediatric Cancer Research Alliance. Jun 2011 - May 2012.
|
Maryam Fouladi, MD, MSc
Medical Director, Neuro-Oncology Program
serves as chair for the CNS Tumor New Agents/Relapse Committee for the Children’s Oncology Group, and as member of the Steering Committee for the COG CNS Tumor Committee and the Collaborative Ependymoma Research Network (CERN). She serves as local and national study chair for active open clinical trials that test new approaches to treat children with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.
513-636-4266
maryam.fouladi@cchmc.org
Maryam Fouladi, MD, MSc
Medical Director, Neuro-Oncology Program
Cincinnati Children's Principal Investigator, Collaborative Ependymoma Research Network
Academic Information
Professor, UC Department of Pediatrics
Show All
Biography
Maryam Fouladi, MD, MSc, graduated from the University of Toronto School of Medicine, and completed her pediatric residency and hematology / oncology fellowship training at the Hospital for Sick Children in Toronto, Canada. Dr. Fouladi then completed her neuro-oncology fellowship training at St. Jude Children's Research Hospital, and later completed further training in the molecular pharmacology department at St. Jude before becoming a neuro-oncology faculty member in 2000. She served as the Chair of the Phase I Committee at St. Jude. Dr. Fouladi moved to Cincinnati Children's in 2008 to direct the neuro-oncology program. She is currently chair for the CNS Tumor New Agent Committee for the Children’s Oncology Group. She is a member of the Steering Committee for the COG CNS Tumor Committee as well as the Developmental Therapeutics group at COG, and is a member of the Collaborative Ependymoma Research Network (CERN). She serves as local and national study chair (through CERN, COG and the Pediatric Brain Tumor Consortium) for clinical trials that test new approaches to treat children with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.
Education and Training
BS: Human Biology, University of Toronto, Toronto, Canada, 1987.
MD: University of Toronto, Toronto, Canada, 1991.
MSc: Institute of Medical Science, University of Toronto, Toronto, Canada, 2002.
Publications
View PubMed Publications
Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele S. Severe Allergic Reactions to Thiol-based Cytoprotective Agents Mesna and Amifostine in a Child With a Supratentorial Primitive Neuroectodermal Tumor. J Pediatr Hematol Oncol. 2011 Aug;33(6):e250-2. Phillips CL, Miles L, Jones BV, Sutton M, Crone K, Fouladi M. Medulloblastoma with melanotic differentiation: case report and review of the literature. J Neurooncol. 2011 Jul;103(3):759-64.
Fouladi M, Gururangan S, Moghrabi A, Phillips P, Gronewold L, Wallace D, Sanford RA, Gajjar A, Kun LE, Heideman R. Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer. 2009 Jul 15;115(14):3243-53.
Shih C, Hale GA, Gronewold L, Tong X, Gilger EA, Srivastava DK, Kun LE, Gajjar A, Fouladi M. High-Dose Chemotherapy with Autologous Stem Cell Rescue for Children with Recurrent Malignant Brain Tumors. Cancer. Mar 15;112(6):1345-53.
Fouladi M, Nicholson S, Zhou T, Laningham F, Helton K, et al. A Phase II Study of the Farnesyl Transferase Inhibitor, Tipifarnib, in Children with Recurrent or Progressive High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma: A Children’s Oncology Group Study. Cancer. 2007 Dec 1;110(11):2535-41.
Fouladi M, Laningham F, Wu J, O’Shaughnessy M, Molina K, Broniscer A, Spunt SL, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL. Phase I Study of Everolimus (RAD001) in Pediatric Patients with Refractory Solid Tumors. J Clin Oncol. 2007 Oct 20;25(30):4806-12.
Morris B, Gajjar A, Okuma, J, Yutaka Y, Wallace D, Kun L, Merchant T, Fouladi M, Broniscer A, Robison L, Hudson M. Survival and Late Mortality in Long-term Survivors of Pediatric Central Nervous System Tumors. J Clin Oncol. 2007 Apr 20;25(12):1532-8.
Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicenter trial. Lancet Oncol. 2006 Oct;7(10):813-20. Erratum in: Lancet Oncol. 2006 Oct;7(10):797.
Fouladi M, Blaney S, Young Poussaint T, Freeman B, McLendon R, Fuller C, Adesina A, Hancock M, Danks M, Ivy P, Stewart C, Gajjar A. A Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma (MB), supratentorial primitive neuroectodermal tumors (SPNET) and atypical teratoid rhabdoid tumors (ATRT): A Pediatric Brain Tumor Consortium Study. Cancer. 2006 107:2291-2297. Fouladi M. Histone deacetylase inhibitors. Cancer Invest. 2006 (5):521-7. Merchant T, Fouladi M. Ependymoma: New therapeutic approaches including radiation and chemotherapy. J Neuro Oncol. 2006 3:287-99.
Grants
Phase I Study of MK2206, an AKT inhibitor, in Children with Recurrent Solid Tumors or Leukemia. CancerFree Kids Pediatric Cancer Research Alliance. Jun 2011 - Jun 2012. CERN Clinical Trials Network-Per Patient. Univ of Texas / Anderson Cancer Center. Jul 2009 - Jun 2012. Pediatric Brain Tumor Consortium. National Institutes of Health. Apr 2008 - Apr 2012. #U01CA098543. Children's Oncology Group. National Institutes of Health. Mar 2011 - Mar 2012. #U10 CA 98543.
|
James I. Geller, MD
Medical Director, Kidney and Liver Tumors Program
focuses on children and young adults affected by solid tumors. Dr. Geller's expertise is recognized internationally, as witnessed by his appointments to the Children's Oncology Group (COG) Renal Tumor, Liver Tumor, Retinoblastoma and Central Nervous System (Brain Tumor) Committees. Dr. Geller directs and spearheads local and national studies in these areas, with an emphasis on novel therapeutics.
513-636-4266
james.geller@cchmc.org
James I. Geller, MD
Medical Director, Kidney and Liver Tumors Program
Co-Medical Director, Retinoblastoma Program
Associate Director, Global Cancer Programs
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsDevelopmental therapeutics; renal / liver / retinoblastoma / neuro-oncology Research InterestsElucidating ways to translate the use of biological response modifiers in combination with conventional chemotherapeutics
Biography
James I. Geller, MD, completed his undergraduate training at Dartmouth College, graduate medical training at the Sackler School of Medicine, residency training in pediatrics at New York Medical College and pediatric hematology / oncology training at St. Jude Children's Research Hospital. His current appointment is with the University of Cincinnati and Children's Hospital Medical Center in the capacity of associate professor of pediatrics.
Dr. Geller's clinical and academic interests pertain to children and families affected by solid tumors, including brain tumors. Dr. Geller's expertise is recognized both nationally and internationally in the fields of retinoblastoma, renal tumors, liver tumors and brain tumors, as witnessed by his appointments to the Children's Oncology Group (COG) Rare/Retinoblastoma Committee as both a Steering/Voting Member and as liaison to the COG Young Investigator Committee; the COG Renal Tumor Committee (RTC) as Steering/Voting Member, RTC Sub-Committee Chair of Developmental Therapeutics, and RTC liaison to both the COG Developmental Therapeutics Committee and the Pediatric Preclinical Testing Program Guidance Committee; and to the Central Nervous System (Brain Tumor) Committee as a voting member. Dr. Geller has been an invited speaker at numerous national and international meetings and symposia and spearheads both local and national clinical research initiatives in these areas, with an emphasis on finding new treatment options.
Education and Training
MD: Sackler School of Medicine, 1997. Residency: New York Medical College, 2000. Fellowship: St Jude Children's Research Hospital, 2004. Certification: Pediatrics, 2000, 2007; Pediatric Hematology / Oncology, 2005.
Publications
View PubMed Publications
Geller JI, Meyers AB, Towbin AJ, Serai S, Geller JI, Podberesky DJ. Characterization of pediatric liver lesions with gadoxetate disodium. Pediatr Radiol. 2011 Sep;41(9):1183-97. Pressey JG, Wright JM, Geller JI, Joseph DB, Pressey CS, Kelly DR. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer. 2010 Jul 1;54(7):1035-7. Cripe TP. Adenovirus gene therapy for pediatric cancers: shall we gather at the liver? Pediatr Blood Cancer. 2009 Aug;53(2):133-5. Geller JI, Dome JS. Retroperitoneal lymph node dissection for pediatric renal cell carcinoma. Pediatr Blood Cancer. 2009 Mar;52(3):430. Geller JI, Leslie ND, Yin H. Malignant Rhabdoid Tumor. eMedicine from WebMD. 2009 Dec. Available online. Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar;52(3):346-50. Geller JI. Genetic stratification of Wilms tumor: is WT1 gene analysis ready for prime time? Cancer. 2008 Sep 1;113(5):893-6.
Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, Collins MH. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008 Apr 1;112(7):1607-16.
Geller JI, Dome JS. Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma. Pediatr Blood Cancer. 2006 Apr;46(4):527.
Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. 2004 Oct 1;101(7):1575-83.
Grants
Identification, selection, and validation of rationale molecular targets that result from this High-Risk Wilms ‘TARGET’ initiative. National Institutes of Health. 2009 - 2011.
|
Adrienne M. Hammill, MD, PhD
conducts clinical research on hemangiomas and vascular malformations, focusing on development of new therapies for these conditions and new tools for assessing response to therapy, including novel imaging modalities.
513-636-0673
adrienne.hammill@cchmc.org
Adrienne M. Hammill, MD, PhD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Hemangiomas and vascular malformations; genetic predispositions to cancer
Education and Training
MD: University of Texas Southwestern Medical School, Dallas, TX, 2004.
PhD: University of Texas Southwestern Graduate School of Biomedical Sciences, Dallas, TX, 2004.
Residency: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Fellowship: Cincinnati Children’s Hospital Medical Center.
Certification: Pediatrics, 2008.
Publications
View PubMed Publications
Hammill AM, Conner J, Cripe TP. Oncolytic virotherapy reaches adolescence. Pediatr Blood Cancer. 2010 Dec 15;55(7):1253-63.
|
Trent R. Hummel, MD
focuses on developing novel therapeutics to treat children with all central nervous system tumors including those with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas. Dr. Hummel is leading a national Phase 1 clinical trial investigating temozolomide in combination with vorinostat.
513-803-1126
trent.hummel@cchmc.org
Trent R. Hummel, MD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Neuro-oncology; CNS tumors in neurofibromatosis type 1 and 2 research interests: developing novel therapeutics in central nervous system tumors including those with very poor prognosis such as high grade gliomas and diffuse intrinsic pontine gliomas.
Biography
Trent R. Hummel, MD, completed his graduate medical training at the University of Cincinnati College of Medicine, residency training in pediatrics at Children's Hospital Medical Center of Akron and pediatric hematology/oncology training at Cincinnati Children's Hospital Medical Center. His current appointment is with the University of Cincinnati and Children's Hospital Medical Center in the capacity of assistant professor of pediatrics. Dr. Hummel's clinical and academic interests pertain to children and families affected by central nervous system tumors. He is a member of the Central Nervous System (Brain Tumor) Committee in the Children's Oncology Group (COG) as well as CCHMC's co-principal investigator for the Pediatric Brain Tumor Consortium (PBTC). Dr. Hummel focuses on developing novel therapeutics to treat children with all central nervous system tumors including those patients with neurofibromatosis type 1 and 2 related CNS tumors and very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.
Education and Training
BS: Eastern Mennonite University, 1997.
MD: University of Cincinnati College of Medicine, 2001.
Residency: Children’s Hospital Medical Center of Akron, Akron, Ohio, 2004.
Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, 2007; Research Fellow, Division of Experimental Hematology, Cincinnati Children’s Hospital Medical Center, 2008.
Certification: American Board of Pediatrics, 2004. Pediatrics, 2004. Pediatric Hematology / Oncology, 2011.
Publications
View PubMed Publications
Hummel TR, Chow LM, Fouladi M, Franz D. Pharmacotherapeutic Management of Pediatric Gliomas: Current and Upcoming Strategies. Pediatric Drugs. 2012. Hummel TR, Miles L, Mangano FT, Jones BV, Geller JI. Clinical heterogeneity of desmoplastic infantile ganglioglioma: a case series and literature review. J Pediatr Hematol Oncol. 2012 Aug;34(6):e232-6. Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu G. Visual outcomes in children with neurofibromatosis type 1–associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012 Jun;14(6):790-7. Sanchez-Pinto LN, Laskin BL, Jodele S, Hummel TR, Yin HJ, Goebel J. BK virus nephropathy in a pediatric autologous stem-cell transplant recipient. Pediatr Blood Cancer. 2011 Mar;56(3):495-7. Hummel T, Anyane-Yeboa A, Mo J, Towbin A, Weiss B. Response of NF1-Related Plexiform Neurofibroma to High Dose Carboplatin. Pediatr Blood Cancer. 2011 Mar;56(3):488-90. Hummel TR, Jessen WJ, Miller SC, Kluwe L, Mautner V, Wallace M, Lázaro C, Page G, Worley P, Aronow B, Schorry E, Ratner N. Gene Expression Analysis Identifies Potential Biomarkers of Neurofibromatosis Type 1 Including Adrenomedullin. Clin Cancer Res. 2010 Oct 15;16(20):5048-57. Hummel T, Hord J. Favorable Response to Soft Tissue Sarcoma Therapy in
Adolescent with Embryonal Renal Sarcoma. Pediatr Blood Cancer. 2004 Jul;
43(1):70-2.
|
Benjamin E. Mizukawa, MD
is trained in pediatric hematology/oncology with a research emphasis in leukemia biology and novel therapeutics. His work is focused on understanding the role of small Rho GTPases in myeloid leukemia development and progression, with the translational goal of identifying new targets for drug development.
513-636-1335
benjamin.mizukawa@cchmc.org
Benjamin E. Mizukawa, MD
Academic Information
Instructor, UC Department of Pediatrics
Show All
Specialties
Pediatric leukemia and lymphoma; investigation of the role of small Rho GTPases in leukemogenesis and leukemic stem cell biology and their potential as therapeutic targets in acute myeloid leukemia; development of xenograft models for use in testing novel therapeutics
Education and Training
MD: University of Utah, Salt Lake City, UT, 2004.
Residency: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Fellowship: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Certification: Pediatrics, 2008
Pediatric Hematology/Oncology, 2011
Publications
View PubMed Publications
Wunderlich M, Mizukawa B, Chou FS, Sexton C, Shrestha M, Saunthararajah Y, Mulloy JC. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood. Epub ahead of print. 2013. Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, Goyama S, Mizukawa B, Shen S, Marcucci G, Mulloy JC. The THPO/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO. Blood. 2012;120(4):709-19. Mizukawa B, Wei J, Shrestha M, Wunderlich M, Chou FS, Griesinger A, Harris CE, Kumar AR, Zheng Y, Williams DA, Mulloy JC. Inhibition of Rac GTPase signaling and downstream pro-survival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. Blood 118(19):5235-45, 2011. Mizukawa B, George A, Pushkaran S, Weckbach L, Kalinyak K, Heubi JE, Kalfa TA. Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. Pediatr Blood Cancer 56(5): 840-2, 2011. Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M, Mulloy JC. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF, and IL-3. Leukemia, 2010; 24(10):1785-8.
Grants
Characterization of Rho GTPases in acute myeloid leukemia (AML) and their potential as therapeutic targets. Principal Investigator. Pediatric Scientist Development Program (PSDP) Fellowship. 2008 - 2011. Targeting Leukemia Cell Interaction with the Marrow Niche. Sub-Investigator. Child Health Research Career Development Award (CHRCDA) NIH K12. 2011 - 2012. Targeting Cdc42 in Leukemia Stem Cells. Principal Investigator. Procter Scholar Award. Cincinnati Children's Hospital Research Foundation. 2012 - 2013.
|
Rajaram Nagarajan, MD, MS
Associate Director, Oncology Clinical Operations
focuses on quality of life and outcomes following cancer therapy. His large collaborative studies involve the Children’s Oncology Group (COG), the Children's Cancer Survivor Study (CCSS) and National Children’s Hospital and Related Institutions (NACHRI) initiative. Dr. Nagarajan co-directs the Long-Term Follow-up Program which follows over 1,400 survivors, a unique program that follows “children” who are now well into adulthood.
513-636-0670
rajaram.nagarajan@cchmc.org
Rajaram Nagarajan, MD, MS
Associate Director, Oncology Clinical Operations
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsBone tumors; late effects of pediatric cancer therapy Research InterestsOutcomes following cancer therapy and bone sarcomas
Education and Training
BA: Pre-Medical Sciences, Lehigh University, Bethlehem, PA, 1991.
MD: Medical College of Pennsylvania, Philadelphia, PA, 1995.
Internship and Residency: Pediatrics, Medical College of Virginia, Richmond, VA, 1998.
Fellowship Training: Hematology / Oncology / BMT, University of Minnesota, Minneapolis, MN, 2002.
MS: Clinical Research, University of Minnesota, Minneapolis, MN, 2002. Certifications: Pediatrics, Pediatric Hematology / Oncology.
Publications
View PubMed Publications
Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, Sklar C, Mertens A, Yasui Y, Robison LL, Marina N. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the childhood cancer survivor study. Cancer. 2011 Feb 1;117(3):625-34. Rayburg M, Towbin A, Yin H, Maugans T, Maurer B, Nagarajan R, Weiss B. Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide. Pediatr Blood Cancer. 2009 Dec;53(6):1111-3. Nagarajan R. Quality of life (QOL) in patients with osteosarcoma. Recent Results Cancer Res. 2009;179:339-44. Nagarajan R, Mogil R, Neglia JP, Robison LL, Ness KK. Self-reported global function among adult survivors of childhood lower-extremity bone tumors: a report from the Childhood Cancer Survivor Study (CCSS). J Cancer Surviv. 2009 Mar;3(1):59-65.
Zebrack BJ, Zevon MA, Turk N, Nagarajan R, Whitton J, Robison LL, Zeltzer LK. Psychological distress in long-term survivors of solid tumors diagnosed in childhood: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2007 Jul;49(1):47-51.
Khan K, Schwarzenberg SJ, Sharp H, Jessurun J, Gulbahce HE, Defor T, Nagarajan R. Diagnostic endoscopy in children after hematopoietic stem cell transplantation. Gastrointest Endosc. Sep 2006;64(3):379-85.
Schultz KA, Ness KK, Nagarajan R, Steiner ME. Adnexal masses in infancy and childhood. Clinical Obstetrics and Gynecology. Sep 2006; 49(3):464-79.
Nagarajan R, Clohisy D, Weigel B. New paradigms for therapy for osteosarcoma. Curr Oncol Rep. 2005 Nov;7(6):410-4.
Nagarajan R, Robison LL. Pregnancy outcomes in survivors of childhood cancer. J Natl Cancer Inst Monogr. 2005;(34):72-6. Book ChaptersSpector LG, Ross JA, Nagarajan R. Epidemiology of bone and soft tissue sarcomas. In Pappo A (Ed.) Pediatric Bone and Soft Tissue Tumors. 1st ed. Berlin: Springer-Verlag, 2006.
|
Maureen M. O'Brien, MD, MS
Associate Director, Leukemia / Lymphoma Program
is a clinical researcher developing new therapies for children, adolescents, and young adults with leukemia and lymphoma including combination of the mTOR inhibitor sirolimus with chemotherapy for patients with relapsed acute lymphoblastic leukemia. Her other research interests include improvements in the supportive care of patients with cancer, with a focus on identification of genetic risk factors and biomarkers for chemotherapy-related toxicity and infectious complications.
513-803-1678
maureen.obrien@cchmc.org
Maureen M. O'Brien, MD, MS
Associate Director, Leukemia / Lymphoma Program
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsLeukemia; lymphoma Research InterestsMolecular etiology of pediatric leukemias, especially in children with Down syndrome; novel therapeutics for relapsed and high-risk leukemia and lymphoma
Education and Training
MD: Harvard Medical School, Boston, MA, 2000.
Residency: Boston Combined Residency Program, Boston Children's Hospital and Boston Medical Center, Boston, MA, 2003.
Fellowship: Stanford University School of Medicine, Stanford, CA, 2007.
MS: Stanford University, Stanford, CA, 2008.
Certification: Pediatrics, 2003; Pediatric Hematology/Oncology, 2009.
Publications
View PubMed Publications
Spicakova T, O'Brien MM, Duran GE, Sweet-Cordero A, Sikic BI. Expression and silencing of the microtubule-associated protein Tau in breast cancer cells. Mol Cancer Ther. 2010 Nov;9(11):2970-81. O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 May;54(5):694-702. O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol. 2010 Mar 1;28(7):1232-9. Jeng MR, O’Brien M, Wong W, Zoland J, Lea J, Tang N, Glader B. Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia. Haemophilia. 2009 Nov 15(6):1272-80. Donaldson SS, O'Brien MM. Understanding the risk of second malignant tumors in children with Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):4-5. O’Brien MM, Lee-Kim Y, George T, McClain K, Twist C, Jeng M. Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis: case series and review of the literature. Pediatr Blood Cancer. 2008 Feb 50(2):381-3 O’Brien MM, Taub JW, Chang MN, Massey GV, Stine KC, Raimondi SC, Becton D, Ravindranath Y, Dahl GV. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children’s Oncology Group Study POG 9421. J Clin Oncol. 2008 Jan 26(3):414-420.
|
Christine L. Phillips, MD
is a clinical oncologist with a clinical and translational research focus on the development of novel therapies for pediatric leukemia and in leukemia pharmacogenetics. Recent work has involved examining common genetic polymorphisms and their contribution to efficacy of therapy and risk for side effects in patients with acute myeloid leukemia.
513-803-1126
christine.phillips@cchmc.org
Christine L. Phillips, MD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Leukemia and lymphoma; leukemia pharmacogenetics; translational and clinical development of new drugs for high-risk and relapsed leukemias
Biography
Christine Phillips, MD, is an oncologist with a clinical focus on leukemia and lymphoma and a clinical and translational research focus on the development of novel therapies for pediatric leukemia and in leukemia pharmacogenetics.
Dr. Phillips earned her undergraduate degree in biochemistry and her medical degree from Indiana University, completed her residency in pediatrics at Children’s Memorial Hospital in Chicago, and her fellowship in pediatric hematology/oncology at Cincinnati Children’s, where she was co-chief fellow. She was a 2008 Hyundai Hope on Wheels Foundation Scholar.
Education and Training
MD: Indiana University School of Medicine, Indianapolis, IN, 2002.
Residency: Pediatrics, Children’s Memorial Hospital, Chicago, IL, 2005.
Fellowship: Pediatric Hematology/Oncology, Cincinnati Children’s Hospital Medical Center, 2010. Certification: Pediatrics, 2005; Pediatric Hematology/Oncology, 2011.
Publications
View PubMed Publications
Phillips CL, Miles L, Jones BV, Sutton M, Crone K, Fouladi M. Medulloblastoma with Melanotic Differentiation: Case Report and Review of the Literature. J Neurooncol. 2011 Jul;103(3):759-64.
Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley ITW, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 Polymorphism Increases Susceptibility to Childhood Acute Myeloid Leukemia. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.
|
Brian K. Turpin, DO
Academic Information
Instructor, UC Department of Pediatrics
Show All
Biography
Brian K. Turpin, DO, completed his undergraduate training at the University of Missouri, graduate medical training at the Kansas City University of Medicine and Biosciences, and pediatric residency and hematology / oncology fellowship at Cincinnati Children’s Hospital Medical Center where he served as co-chief fellow. Dr. Turpin’s clinical and academic interests pertain to children and young adults with solid tumors, particularly sarcomas and neuroblastomas, with a research focus on the development of new drugs and clinical trials for patients with relapsed cancer.
Education and Training
DO: Kansas City University of Medicine and Biosciences. Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center. Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cancer and Blood Diseases Institute.
Publications
View Dr. Turpin's PubMed Publications
Turpin BK, Morris VR, Lemen L, Weiss BD, Gelfand MJ. Minimizing nuclear medicine technologist radiation exposure during 131I-MIBG therapy. Health Phys. 2013 Feb; 104(2 Suppl 1):S43-6. Trehan I, Turpin BK. Neonatal respiratory distress due to bilateral dacrocystoceles. J Pediatr. 2008 Sep;153(3):438. Turpin B, Tobias JD. Perioperative management of a child with short-chain acyl-CoA dehydrogenase deficiency. Paediatr Anaesth. 2005 Sep;15(9):771-7. Cogar BD, Groshong TD, Turpin BK, Guajardo JR. Chylothorax in Henoch-Schonlein purpura: a case report and review of the literature. Pediatr Pulmonol. 2005 Jun;39(6):563-7.
|
Brian D. Weiss, MD
Associate Director for Safety and Compliance, Cancer and Blood Diseases Institute
focuses on new approaches to treat high-risk Neuroblastoma, including novel ways to use 131I-MIBG therapy, and on targeted agents for neurofibromatosis type 1-related tumors and malignancies. In addition, he is researching methods and processes to ensure error-free delivery of therapy.
513-636-9863
brian.weiss@cchmc.org
Brian D. Weiss, MD
Associate Director for Safety and Compliance, Cancer and Blood Diseases Institute
Cincinnati Children's Principal Investigator, New Approaches to Neuroblastoma Therapy Consortium
Medical Director, Neuroblastoma Program
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Targeted agents for neurofibromatosis type 1-related malignancies; high-risk neuroblastoma and 131I-MIBG treatment of neuroblastoma; new approaches to targeting and killing neuroblastoma cells
Education and Training
MD: Northwestern University Medical School, Chicago, IL, 1993. Residency and Chief Residency: Pediatrics, University of California, San Francisco, CA, 1993-1997. Fellowship: Pediatric Hematology/Oncology, University of California, San Francisco, CA, 1997-2000. Certification: National Medical Board; Pediatrics;1996, 2002; Pediatric Hematology-Oncology, 2000, 2007
Publications
View PubMed Publications
Hummel T, Anyane-Yeboa A, Mo J, Towbin A, Weiss B. Response of NF1-related plexiform neurofibroma to High-Dose Carboplatin. Pediatr Blood Cancer. 2011 Mar;56(3):488-90.
Rayburg M, Towbin A, Yin H, Maugans T, Maurer B, Nagarajan R, Weiss B. Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide. Pediatr Blood Cancer. 2009 Dec;53(6):1111-3.
Weiss B, Geiger H, Davies SM. Possible leukemogenic potential of temozolomide. Pediatr Blood Cancer. 2009 Apr;52(4):553. Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res. 2009 Mar;33(3):355-62. Wagner LM, McLendon RE, Yoon KJ, Weiss BD, Billups CA, Danks MK. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5418-25. Geiger H, Schleimer D, Nattamai KJ, Dannenmann SR, Davies SM, Weiss BD. Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood. 2006 Apr 1;107(7):3010-1. Book ChaptersWeiss B and Shannon K. Preliminary Examples of Preclinical Trials. In Mouse Models of Cancer, Eric Holland (Ed). Wiley-Liss, 2004.
Grants
Children's Oncology Group Chairs Grant. National Institutes of Health (Children's Oncology Group)
U10 CA 098543 Mar 2011 - Feb 2012.
|
Susanne Wells, PhD
Director, Epithelial Carcinogenesis and Stem Cell Program
focuses on new targets of the HPV E6/E7 oncogenes, and characterizing these as potential risk factors for HPV infection and transformation. Research approaches include bioinformatics; analyses of primary, transformed and 3D cell culture systems; and mouse tumor models to facilitate translational endeavors. Visit the Wells Lab.
513-636-5986
susanne.wells@cchmc.org
Susanne Wells, PhD
Director, Epithelial Carcinogenesis and Stem Cell Program
Director, Postdoctoral Office
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Squamous cell carcinoma; mechanisms by which the HPV oncogenes subvert the host cell machinery to promote abnormal cell growth and cancer; role of specific cellular HPV targets in viral replication and cellular transformation Visit the Wells Lab.
Biography
Susanne Wells graduated from the University of Konstanz, Germany, with a degree in Biology. She completed her PhD in Molecular Biology at the State University of Stony Brook, NY, and her Postdoctoral Fellowship at Harvard Medical School, MA. Dr. Wells moved to Cincinnati Children's Hospital Medical Center in 2002 to study human papillomavirus infection and associated carcinogenesis.
Education and Training
BS: Biology, University of Konstanz, Germany, 1992.
PhD: Molecular Genetics, State University of Stony Brook, NY, 1997.
Postdoctoral Fellowship: Molecular Virology, Harvard Medical School, Boston, MA.
Publications
View PubMed Publications
Privette Vinnedge, L. M., Kappes, F., Nassar, N. and Wells, S. I. 2012. Stacking the DEK: from chromatin topology to cancer stem cells. Cell Cycle. In process. Romick-Rosendale, L. E., Lui, V. W., Grandis, J. R., and Wells, S. I. 2012. The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma. Mutation Research. In press. Privette Vinnedge, L. M., Ho, S.-M., Wikenheiser-Brokamp, K. A., Wells, S. I. 2012. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer. PLOS ONE, In process. Yablonska, S., Hoskins, E. E., Wells, S. I., Khan, S. A. 2012. Identification of miRNAs dysregulated in human foreskin keratinocytes (HFKS) expressing the human papillomavirus (HPV) Type 16 E6 and E7 oncoproteins. Epub ahead of print. Hoskins, E. E., Morreale, R. J., Werner, S. P., Higginbotham, J. M., Laimins, L. A., Lambert, P. F., Brown, D. R., Gillison, M. L., Nuovo, G. J., Witte, D. P., Kim, M.-O, Davies, S. M., Mehta, P. A., Butsch Kovacic, M., Wikenheiser-Brokamp, K. A., Wells, S. I. 2012. The Fanconi anemia pathway limits human papillomavirus replication. Journal of Virology. 86; 8131-8138 Wise-Draper, T. M., Draper, D. J., Gutkind, J. S., Molinolo, A. A., Wikenheiser-Brokamp, K. A., and Wells, S. I., 2012. Future directions and treatment strategies for head and neck squamous cell carcinomas. Transl. Res. 160; 167-177. Morrison, M. A., Morreale, R. J., Akunuru, S., Kofron, M., Zheng, Y., Wells, S. I. 2011. Targeting the human papillomavirus E6 and E7 oncogenes through expression of the BPV1 E2 protein stimulates cellular motility. Journal of Virology. 85: 10487-10498. Kavanaugh, G. M., Wise-Draper, T. M., Morreale, R. J., Morrison, M. A., Gole, B., Schwemberger, S., Tichy, E. D., Lu, L., Babcock, G. F., Wells, J. M., Drissi, R., Bissler, J. J., Stambrook, P. J., Andreassen, P. R., Wiesmüller, L., Wells, S. I. 2011. The human DEK oncogene regulates DNA damage response signaling and repair. Nucl. Acids Res. 39: 7465-7476. Privette Vinnedge, L. M., McClaine, R., Wagh, P. K., Wikenheiser-Brokamp, K. A., Waltz, S. E., Wells, S. I. 2011. The human DEK oncogene stimulates b-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene. 30: 2741-2752. Spence, J. R., Mayhew, C. N., Rankin, S. A., Kuhar, M. F., Vallance, J. E., Tolle, K., Hoskins, E. E., Kalinichenko, V. V., Wells, S. I., Zorn, A. M., Shroyer, N. F., and Wells, J. M. 2011. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature. 470: 105-109.
Grants
Role and regulation of the human DEK proto-oncogene. Principle Investigator. National Institutes of Health. 2006 - 2011. Fanconi Anemia and HPV transformation. Principle Investigator. National Institutes of Health. 2010 - 2015. #2RO1 CA102357. Fanconi Anemia as a Model for Susceptibility to Human Papillomavirus Infection. Principle Investigator. National Institutes of Health. 2011 - 2016. #1RO1 HL108102-01.
|
